title: In vitro antimicrobial activity of Fill Canal, Sealapex, Mineral Trioxide Aggregate, Portland cement and EndoRez.
abstract: OBJECTIVE
  To determine in vitro the antimicrobial activity of Fill Canal, Sealapex, Mineral Trioxide Aggregate (MTA), Portland cement and EndoRez on various species of microorganisms.
  
  
  METHODS
  The diffusion method on Müller-Hinton agar (MH) was employed. A base layer was made using MH agar and five wells were made by removing agar at equidistant points. Sealers were placed into the wells immediately after manipulation. The microorganisms Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922, Micrococcus luteus ATCC 9341, Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC 12228, Pseudomonas aeruginosa ATCC 27853 and Candida albicans ATCC 10231 were seeded by pour plate. The plates were kept at room temperature for 2 h for prediffusion and then incubated at 37 degrees C for 24 h. Aliquots of 10 mL of 0.05% triphenyltetrazolium chloride gel were added for optimization and the zones of inhibition were measured.
  
  
  RESULTS
  Sealapex and Fill Canal demonstrated antimicrobial activity for all strains. For MTA and Portland cement, only E. coli was not inhibited. No antimicrobial activity was detected for EndoRez.
  
  
  CONCLUSIONS
  In this laboratory study, Fill Canal, Sealapex, MTA and Portland cement presented antimicrobial activity whilst EndoRez did not.
authors: Endodontic Division, Hospital de Reabilitação de Anomalias Craniofaciais, Universidade de São Paulo, Bauru, Brazil.
authors: C R
authors: CR
authors: Sipert
authors: R P
authors: RP
authors: Hussne
authors: C K
authors: CK
authors: Nishiyama
authors: S A
authors: SA
authors: Torres
mesh_terms: D017607:Aluminum Compounds / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001466:Barium Sulfate / Q000494:pharmacology; D001729:Bismuth / Q000494:pharmacology; D001881:Borates / Q000494:pharmacology; D017610:Calcium Compounds / Q000494:pharmacology; D002126:Calcium Hydroxide / Q000494:pharmacology; D002176:Candida albicans / Q000187:drug effects; D003188:Composite Resins / Q000494:pharmacology; D004338:Drug Combinations; D013293:Enterococcus faecalis / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D005054:Eugenol / Q000494:pharmacology; D006801:Humans; D008422:Materials Testing; D016982:Micrococcus luteus / Q000187:drug effects; D010087:Oxides / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012117:Resins, Synthetic / Q000494:pharmacology; D012387:Root Canal Filling Materials / Q000494:pharmacology*; D012459:Salicylates / Q000494:pharmacology; D017640:Silicates / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects; D015034:Zinc Oxide / Q000494:pharmacology
chemical_list: D017607:Aluminum Compounds; D000890:Anti-Infective Agents; D001881:Borates; D017610:Calcium Compounds; D003188:Composite Resins; D004338:Drug Combinations; C481259:EndoRez; D010087:Oxides; D012117:Resins, Synthetic; D012387:Root Canal Filling Materials; D012459:Salicylates; D017640:Silicates; C086631:mineral trioxide aggregate; C055601:Sealapex; D001466:Barium Sulfate; D005054:Eugenol; C038425:Fillcanal; D002126:Calcium Hydroxide; C031293:calcium silicate; D015034:Zinc Oxide; D001729:Bismuth